GK
REGN icon

Glen Kacher’s Regeneron Pharmaceuticals REGN Stock Holding History

Glen Kacher’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-52,100
Closed -$25.4M – 47
2020
Q1 		$25.4M Buy
+52,100
New +$21.5M 1.34% 35

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Glen Kacher's REGN Position: Q2 2020 in Review

Glen Kacher sold out of Regeneron Pharmaceuticals (REGN) in Q2 2020, closing a stake of 52,100 shares — an estimated $25.4M sold.

Glen Kacher first reported a position in REGN in Q1 2020 and held it in 1 quarter. The position peaked at $25.4M in Q1 2020. 933 funds tracked by Wall St. Rank hold REGN as of Q2 2020.

  • Glen Kacher reported no remaining Regeneron Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Glen Kacher sold 52,100 Regeneron Pharmaceuticals shares in Q2 2020, an estimated $25.4M.
  • Glen Kacher first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 1 quarter.
  • Glen Kacher's Regeneron Pharmaceuticals position peaked at $25.4M in Q1 2020.
  • 933 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2020.

Based on Light Street Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.